Expert Interview
A Second Look: Discussing the results from the Phase Ib clinical trial of CT-388, a dual GLP-1/GIP receptor agonist in development by Genentech/Roche as a once-weekly subcutaneous injection for the treatment of obesity and type 2 diabetes.
Ticker(s): RHHBYInstitution: East Coast Medical Associates
- Treats 30 patients with Thyroid Eye Disease
- treats 15 patients with chronic TED and has prescribed TEPEZZA for 10 patients
- familiar with the recently announced positive topline results from the Phase 4 clinical trial (NCT04583735) evaluating TEPEZZA for the treatment of adults with chronic TED and low CAS
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
